Protalix BioTherapeutics (PLX) Current Deferred Revenue (2010 - 2025)

Protalix BioTherapeutics' Current Deferred Revenue history runs 16 years deep, the most recent figure standing at $2.0 million for Q1 2025.

• In Q1 2025, Current Deferred Revenue fell 81.88% year-over-year to $2.0 million; the TTM figure through Mar 2025 stood at $2.0 million (down 81.88% YoY), while the FY2022 annual figure was $13.2 million, up 54.13% from the prior year.
• Current Deferred Revenue was $2.0 million for Q1 2025 at Protalix BioTherapeutics, down from $12.7 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $18.1 million in Q2 2021 to a low of $2.0 million in Q1 2025.
• Historically, Current Deferred Revenue has averaged $11.0 million across 5 years, with a median of $11.8 million in 2022.
• The sharpest annual moves came in 2021 and 2022: Current Deferred Revenue tumbled 86.54% in 2021, then jumped 360.98% in 2022.
• A 5-year view of Current Deferred Revenue shows it stood at $8.5 million in 2021, then soared by 54.13% to $13.2 million in 2022, then fell by 10.53% to $11.8 million in 2023, then grew by 7.68% to $12.7 million in 2024, then tumbled by 84.25% to $2.0 million in 2025.
• The last three Current Deferred Revenue figures came in at $2.0 million (Q1 2025), $12.7 million (Q2 2024), and $11.0 million (Q1 2024), per Business Quant data.